Here’s the latest on Xtalks.com: Amgen’s cholesterol
drug, Repatha, has been shown to cut the risk of cardiovascular events in a recent clinical
trial. More detailed results of the study are being presented at the American College
of Cardiology 66th Annual Scientific Session. Hello I’m Sarah Hand, Editor and Webinar Moderator
for Xtalks.com, and welcome to this edition of Xtalks Vitals. Along with reducing the
risk of heart attacks, strokes and death in patients, the cholesterol-lowering PCSK9 inhibitor
was on-par with the placebo in terms of its effect on cognitive function. As rare instances
of neurocognitive events have occurred in some late-stage PCSK9 clinical trials, these
findings help ease concerns that the drug could impair cognition.
The Phase III FOURIER trial involved approximately 27,500 patients who had previously experienced
a heart attack, ischemic stroke or symptomatic peripheral artery disease. These patients
were all on optimized statin therapy, and were randomly assigned to receive Repatha
or a placebo injection, administered bi-weekly. Repatha is a monoclonal antibody that inhibits
the PCSK9 protein. By binding to PCSK9, Repatha prevents the protein from binding to the LDL
receptor, which is responsible for removing LDL cholesterol. Repatha allows the receptor
to perform this function by removing interference from PCSK9, thereby reducing levels of LDL
cholesterol in the blood. Cardiovascular disease is the number one cause
of death globally. Approximately 11 million individuals in the US have atherosclerotic
cardiovascular disease and/or familial hypercholesterolemia that remains uncontrolled with statins alone.
Subscribe to the Xtalks YouTube channel by clicking the subscribe button below, and visit
xtalks.com for more information on this story and others like it in the life science industry.